Topical drug delivery systems in dermatology: A review of patient adherence issues

Expert Opinion on Drug Delivery

Volumn 9, Issue 10, 2012, Pages 1263-1271

  Tan, Xi ^a   Feldman, Steven R ^b   Chang, Jongwha ^c   Balkrishnan, Rajesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Compliance; Dermatology; Medication adherence; Patient adherence; Topical drug; Topical medication; Topical vehicle

Indexed keywords

BENZOYL PEROXIDE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLINDAMYCIN PHOSPHATE; COAL TAR; COLECALCIFEROL; CORTICOSTEROID; DERMATOLOGICAL AGENT; DESONIDE; DITHRANOL; RETINOIC ACID; RETINOID; TRIAMCINOLONE;

ACNE; ATOPIC DERMATITIS; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MEDICAL RESEARCH; PATIENT COMPLIANCE; PREVALENCE; PSORIASIS; REVIEW; SELF REPORT; SKIN DISEASE; SYSTEMATIC REVIEW; TOPICAL TREATMENT;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; PSORIASIS; SKIN DISEASES;

EID: 84866863869     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.711756     Document Type: Review

References (65)

1. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012;73(5): 691-705
2. World Health Organisation S. Adherence to long-term therapies: evidence for action. World Health Organization; Geneva, Switzerland: 2003
3. Berry SD, Quach L, Procter-Gray E, et al. Poor Adherence to medications may be associated with falls. J Gerontol A Biol Sci Med Sci 2010;65A(5):553-8
4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5):487-97
5. Nolan BV, Feldman SR. Dermatologic medication adherence. Dermatol Clin 2009;27(2):113-20
6. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004;151(4):895-7
7. Wolf J. Medication adherence: a key factor in effective management of rosacea. Adv Ther 2001;18(6):272-81
8. Fischer G. Compliance problems in paediatric atopic eczema. Australa J Dermatol 1996;37:S10-13
9. Kinney MA, Feldman SR. What's new in the management of psoriasis? G Ital Dermatol Venereol 2009;144(2):103-17
10. Dréno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 2010;49(4):448-56
11. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis (New York, N.Y.) 2010;86(2):103
12. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003;149(3):582-9
13. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol 2003;49(4):651-4
14. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004;51(2):212-16
15. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008;59(1):27-33
16. van de Kerkhof PCM, de Hoop D, de Korte J, et al. Patient Compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200(4):292-8
17. Cook-Bolden F, Eichenfield LF, Fried R, et al. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol 2008;7(12):1129-36
18. Pawin H, Beylot C, Chivot M, et al. Creation of a tool to assess adherence to treatments for acne. Dermatology 2009;218(1):26-32
19. Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of double strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2002;13(3):111-17
20. Cunliffe WJ, Fernandez C, Bojar R, et al. An observer blind, parallel group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. J Dermatolog Treat 2005;16(4):213-18
21. McEvoy B, Nydegger R, Williams G. Factors related to patient compliance in the treatment of acne vulgaris. Int J Dermatol 2003;42(4):274-80
22. Zaghloul SS, Cunliffe WJ, Goodfield MJD. Objective assessment of compliance with treatments in acne. Br J Dermatol 2005;152(5):1015-21
23. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56(2):211-16
24. Serup J, Kettis Lindblad A, Maroti M, et al. To follow or not to follow dermatological treatment-A review of the literature. Acta Dermatol Venereol 2006;86(3):193-7
25. Krejci-Manwaring J, McCarty MA, Camacho F, et al. Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol 2006; 54(5):S235-6
26. Storm A, Benfeldt E, Andersen SE, Serup J. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol 2008;59(6):975-80
27. Gupta G, Mallefet P, Kress DW, Sergeant A. Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol 2009;161(2):221-7
28. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008;59(6):1009-16
29. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41(4):581-3
30. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006;55(4):607-13
31. Ivens UI, Steinkjer B, Serup J, Tetens V. Ointment is evenly spread on the skin, in contrast to creams and solutions. Br J Dermatol 2001;145(2):264-7
32. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011;222(4):363-74
33. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57(1):81-3
34. Lott R, Taylor SL, O'Neill JL, et al. Medication adherence among acne patients: a review. J Cosmet Dermatol 2010;9(2):160-6
35. Baker M, Tuley M, Busdiecker FL, et al. Adapalene gel 0.1% is effective and well tolerated in acne patients in a dermatology practice setting. Cutis 2001;68(4 Suppl):41-7
36. Yentzer BA, Alikhan A, Teuschler H, et al. An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. J Am Acad Dermatol 2009;60(5):879-80
37. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther 2006;19(4):224-36
38. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol 2006;7(4):231-6
39. Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology 2008;217(4):309-14
40. Misery L. Why is there poor adherence to topical corticosteroid therapy in atopic dermatitis? Expert Rev Dermatol 2012;7(1):5-7
41. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011;165(4):808-14
42. Yentzer BA, Camacho FT, Young T, et al. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. J Drugs Dermatol 2010;9(4):324-9
43. Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement: implications for dermatology. Am J Clin Dermatol 2001;2(1):7
44. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19(4):357-62
45. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2008;2. Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.pub3.
46. Hodari KT, Nanton JR, Carroll CL, et al. Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat 2006; 17(3):136-42
47. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142(5):931-6
48. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150(7):1509-10
49. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150(7):1377-8
50. Kass MA, Meltzer D, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986;101(5):515-23
51. Cutrona SL, Choudhry NK, Fischer MA, et al. Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manag Care 2010;16(12):929-42
52. Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med 2009;36(2):165-73
53. Hibbard JH, Mahoney ER, Stock R, Tusler M. Do increases in patient activation result in improved self-management behaviors? Health Serv Res 2007;42(4):1443-63
54. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003;4:221-4
55. Kircik LH. Importance of vehicles in acne therapy. J Drugs Dermatol 2011;10(6):s17-s23
56. Buhse L, Kolinski R, Westenberger B, et al. Topical drug classification. Int J Pharm 2005;295(1-2):101-12
57. Kurian A, Barankin B. Delivery Vehicle Advances in Dermatology. 2011.Available from: http://www. skintherapyletter.com/fp/2011/7.2/2.html [Accessed 30 May 2012]
58. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011;25:9-14
59. van de Kerkhof PCM, Kragballe K, Segaert S, Lebwohl M; for the International Psoriasis Council. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council. J Eur Acad Dermatol Venereol 2011;25(10):1130-9
60. Kahanek NR, Gelbard CG, Hebert AA. Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs 2008;17(7):1097-104
61. Nighland M, Yusuf M, Wisniewski S, et al. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis 2006;77(5):313-16
62. Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis 2002;70(5):295-8
63. Wester RC, Patel R, Nacht S, et al. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J Am Acad Dermatol 1991;24(5 Part 1):720-6
64. Koo JYM. Relevance of the COBRA trial in current psoriasis practice. Cutis (New York, N.Y.) 2007;80(5):4
65. West CE, Narahari S, Feldman SR. Calcipotriene foam, 0.005% in mild-to-moderate plaque psoriasis. Expert Rev Dermatol 2012;7(1):17-26